Therapeutic Effects of Aldose Reductase Inhibitor on Experimental Diabetic Neuropathy through Synthesis/Secretion of Nerve Growth Factor
- 30 June 1998
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 151 (2) , 215-220
- https://doi.org/10.1006/exnr.1998.6821
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Nerve Growth Factor Regulates the Expression of Brain-Derived Neurotrophic Factor mRNA in the Peripheral Nervous SystemMolecular and Cellular Neuroscience, 1996
- Reversal of defective peripheral nerve conduction velocity, nutritive endoneurial blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY-121,509, in streptozotocin-induced diabetic ratsJournal of Diabetes and its Complications, 1996
- Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathyAnnals of Neurology, 1995
- Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanismDiabetologia, 1994
- Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioceptive afferentsCell, 1994
- Nerve growth factor administration protects against experimental diabetic sensory neuropathyBrain Research, 1994
- A Placebo‐controlled Double‐blind Study of Epalrestat (ONO‐2235) in Patients with Diabetic NeuropathyDiabetic Medicine, 1993
- Hypoxic neuropathy Does hypoxia play a role in diabetic neuropathy?Neurology, 1989
- A Highly Sensitive Enzyme Immunoassay for Mouse β Nerve Growth FactorJournal of Neurochemistry, 1983
- Distal neuropathy in experimental diabetes mellitusAnnals of Neurology, 1980